Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1

Interventions

Cyclophosphamide 122Cytarabine 112fludarabine 91fludarabine phosphate 80Rituximab 75Azacitidine 74venetoclax 54Methotrexate 52Filgrastim 48Whole-Body Irradiation 45Busulfan 45Tacrolimus 35Etoposide 35Mycophenolic Acid 34Lenalidomide 32Imatinib Mesylate 32Antilymphocyte Serum 32Granulocyte Colony-Stimulating Factor 31Decitabine 31Peripheral Blood Stem Cell Transplantation 29Dexamethasone 29Cyclosporine 29Vincristine 26Melphalan 26Clofarabine 25Alemtuzumab 25Mitoxantrone 24Stem Cell Transplantation 22Radiotherapy 22Dasatinib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × troxacitabine × Other hematologic neoplasm × Clear all
NCT00104468 2008-01-17

Study of Troxatylâ„¢ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)

SGX Pharmaceuticals, Inc.

Phase 1/2 Terminated
50 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00129948 2006-11-03

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

SGX Pharmaceuticals, Inc.

Phase 2 Terminated
211 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡